Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $15.9352W HIGH $43.66
Volume
465.90 K
Value Traded
7.75 M
Short % Float
19.52%
-0.26%Week
-25.59%1 Month
-31.11%3 Month
+36.93%6 Month
-86.98%5 Year
-88.26%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
528.30 M
EPS (TTM)
-5.55
P/E Ratio
-
Ent. Value
302.91 M
Total Shares
20.02 M
Float Shares
16.80 M
Insiders
16.06%
Institutions
86.71%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
NGNE Catalyst Timeline
Dated clinical, regulatory and corporate events for Neurogene Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Neurogene Inc.
262Total events
4Upcoming
55Tier-1 (high impact)
2014 to 2029Coverage
Upcoming catalysts 2
Event history 50
●Grant / FundingCorporate
Compensation Committee approved inducement stock option grants to five new employees
▲Safety Data UpdateNGN-401Clinical Data
NGN-401 at 1E15 vg dose generally well-tolerated (N=35) as of August 10, 2026
Rett syndromesource ↗
▲Equity OfferingCorporate
Oversubscribed public follow-on offering of approximately $144 million gross proceeds
▲Manufacturing MilestoneNGN-401CMC / Inspection
Initiated PPQ campaign to support BLA submission for NGN-401
Rett syndromesource ↗
▲Full ResultsNGN-401Clinical Data
Positive long-term clinical data reported from Phase 1/2 trial of NGN-401
Rett syndromesource ↗
▲Long Term DataNGN-401Clinical Data
Positive long-term Phase 1/2 data for NGN-401 in Rett syndrome (data cutoff June 16, 2026)
Rett syndromesource ↗
▲Enrollment CompleteNGN-401Trial
Successful completion of dosing in Embolden registrational trial of NGN-401 for Rett Syndrome
Rett Syndromesource ↗
◆Oral PresentationNGN-401Presentation
Presentation of additional interim Phase 1/2 clinical data
Rett syndromesource ↗
◆Interim AnalysisNGN-401Trial
Additional interim Phase 1/2 data expected mid-2026
Rett syndromesource ↗
◆Oral PresentationPresentation
Data presentation at ASGCT meeting supporting ICV delivery method
CNS-targeted gene therapysource ↗
◆Poster PresentationNGN-401Presentation
Poster presentation on ICV delivery rationale for NGN-401 at ASGCT 2026
Rett syndromesource ↗
▲Enrollment MilestoneNGN-401Trial
Dosed ~90% of participants in Embolden registrational trial
Rett syndromesource ↗
●Oral PresentationNGN-401Presentation
Presentation at ASGCT Meeting highlighted therapeutic rationale for ICV delivery in CNS-targeted gene therapy, including NGN-401
Rett syndromesource ↗
▲Enrollment CompleteNGN-401Trial
On track to complete dosing in Embolden trial in Q2 2026
Rett syndromesource ↗
▲Breakthrough Therapy DesignationNGN-401Designation
FDA granted Breakthrough Therapy designation for NGN-401
Rett syndromesource ↗
◆Oral PresentationPresentation
Neurogene management to present at 44th Annual J.P. Morgan Healthcare Conference
◆Additional DataNGN-401Clinical Data
Additional data from expanded set of NGN-401 patients
Rett syndromesource ↗
◆Trial InitiationTrial
Initiation of clinical study for discovery-stage candidate
additional area of high unmet needsource ↗
◆Development Candidate NominationPreclinical
Advance one additional product candidate using EXACT into clinic
◆Interim AnalysisNGN-401Trial
Interim efficacy data from first cohort expected in Q4 2024
Rett syndromesource ↗
◆Topline ReadoutNGN-101Clinical Data
Preliminary data from NGN-101 Phase 1/2 trial
CLN5 Batten diseasesource ↗
▲Other Regulator MilestoneNGN-401Ex-US Regulatory
UK MHRA clinical trial application approval received
Rett syndromesource ↗
▲MHRA MilestoneNGN-401Ex-US Regulatory
CTA clearance obtained from UK MHRA for NGN-401
Rett syndromesource ↗
▲Enrollment CompleteNGN-101Trial
Completed enrollment of Cohorts 1 and 2 in Phase 1/2 trial for CLN5 Batten disease
CLN5 Batten diseasesource ↗
▲Partnership / LicenseCorporate
Extended research collaboration with University of Edinburgh by three years
◆Enrollment UpdateNGN-401Trial
On track to dose third pediatric patient in early 1Q:24
Rett syndromesource ↗
▲First Patient DosedNGN-401Trial
First two patients dosed in Phase 1/2 trial of NGN-401
Rett syndromesource ↗
▲Safety Data UpdateNGN-401Clinical Data
NGN-401 well-tolerated with no SAEs or overexpression toxicity to date
Rett syndromesource ↗
Past FDA Catalysts and PDUFA Decisions
How NGNE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-12 | NGN-401 gene therapy | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D22 / 100
Pipeline Score
$50M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 91%
Micro Cap(rank 601 of 660)
Percentile Rank
Neurogene Inc. faces pipeline headwinds (22/100), with $126M risk-adjusted pipeline value, led by NL-201 in Solid Tumor (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NL-201 Small moleculeCompletedNCT04659629 | Solid Tumor | Phase 1 | COMPLETED | 59 | Aug 15, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every NGNE program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| NGN-401 Breakthrough | Rett syndrome | Phase 1/2 | 2026-04-28 | safety profile at the 1E15 vg dose that supports continued advancementRead More | Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene TherapyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| McMinn RachelDirector, Officer (Chief Executive Officer) | Option | 756 1,345,063 held | $25.32 | 09/22/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NGNE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Samsara BioCapital, LLC | 4.4 % (29.4 %) | 54.00 M | 1.72 M |
NGNE Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NGNE ranks across every disease it competes in
Competitive Position is a premium feature
See how NGNE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNGNE News
NGNENeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Inc. announced the approval of non-qualified stock options for five new employees as part of its inducement grants under Nasdaq Listing Rule 5635(c)(4). This decision, made by the Compensation Committee of the Board of Directors, aims to enhance the company's ability to attract talent in the field of genetic medicine. The grants involve a total of 8,340 shares of common stock.
Read more →NGNENeurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Neurogene Inc. announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference. The management will engage in a fireside chat and hold investor meetings on September 15 at 1:00 p.m. ET. This event underscores Neurogene's commitment to advancing genetic therapies for rare neurological diseases.
Read more →NGNENeurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
Neurogene Inc. reported its second quarter 2026 financial results, showcasing significant advancements in its NGN-401 program. The company highlighted positive long-term data from Phase 1/2 trials, indicating durable developmental gains for patients. This progress is crucial for Neurogene's mission to deliver genetic therapies for rare neurological diseases.
Read more →NGNE▲ +7.7%on this news
Neurogene Inc. Announces Pricing of $125 Million Public Offering
Neurogene Inc. has announced the pricing of a public offering amounting to $125 million. This move is part of the company's strategy to raise capital, although further details on the intended use of the funds were not provided. The announcement reflects the company's ongoing efforts to strengthen its financial position.
Read more →NGNE▲ +7.7%on this newsshared move
Neurogene Inc. Announces Proposed Public Offering
Neurogene Inc. has announced a proposed public offering. Details regarding the offering, including the number of shares and pricing, have not been disclosed in the article. The announcement suggests that the company is looking to raise capital, but further information is needed to assess the potential impact.
Read more →NGNENeurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
Neurogene has announced positive long-term clinical data from its Phase 1/2 trial of NGN-401, a gene therapy aimed at treating Rett Syndrome. The results suggest that NGN-401 may be effective in addressing the symptoms associated with this condition. This development marks a significant step forward in the treatment options available for patients with Rett Syndrome.
Read more →NGNE▲ +8%on this news
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
Neurogene has announced the successful completion of dosing in its Embolden™ registrational trial for NGN-401, aimed at treating Rett Syndrome. This milestone marks a significant step forward in developing therapies for this rare condition. The trial's progress is expected to enhance treatment options for patients affected by Rett Syndrome.
Read more →NGNENeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 2, 2026
Neurogene Inc. announced the approval of non-qualified stock options for two new employees as part of its 2025 Inducement Plan. The grants, totaling 17,045 shares, are designed to incentivize new hires in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, promoting long-term commitment to the company.
Read more →NGNENeurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy
Neurogene presented data at the ASGCT meeting that supports the therapeutic rationale for using intraventricular (ICV) delivery methods in CNS-targeted gene therapy. The findings aim to enhance understanding of gene therapy applications in treating central nervous system disorders. Further details on the data and its implications were discussed during the event.
Read more →NGNENeurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
Neurogene has released its financial results for the first quarter of 2026. The report includes recent updates regarding the company's operations and financial performance. However, specific details about the financial results or operational highlights were not provided in the article.
Read more →NGNENeurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
Neurogene Inc. announced an upcoming poster presentation at the ASGCT Annual Meeting, focusing on the benefits of intracerebroventricular (ICV) delivery for CNS-targeted gene therapy, specifically for Rett syndrome. The presentation will showcase preclinical data indicating superior biodistribution of NGN-401 via ICV compared to intrathecal-lumbar administration. Interim results from ongoing trials suggest positive safety and efficacy outcomes.
Read more →NGNENeurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
Neurogene has announced the appointment of Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to its Board of Directors. These appointments are expected to enhance the company's leadership and strategic direction. The new executives bring valuable experience that may contribute to Neurogene's growth and success in the biopharma sector.
Read more →NGNE▲ +8%on this news
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
Neurogene has reported its financial results for the full year 2025, highlighting key updates. The report includes insights into the company's performance and strategic direction. However, specific details on financial metrics or developments were not provided in the article.
Read more →NGNE▲ +8.7%on this news
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 3, 2026
Neurogene Inc. has announced the approval of non-qualified stock options for four new employees as part of its 2025 Inducement Plan. This grant, totaling 32,450 shares, is in accordance with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize new talent. The options will vest over four years, aligning with the company's growth strategy in developing genetic medicines for neurological diseases.
Read more →NGNE▲ +19.4%on this newsshared move
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
Neurogene Inc. has received FDA Breakthrough Therapy designation for NGN-401, a gene therapy aimed at treating Rett syndrome. This designation is based on interim Phase 1/2 trial data showing significant functional improvements in patients. The company plans to complete dosing in its registrational trial by the second quarter of 2026 and present more data in mid-2026.
Read more →About Neurogene Inc.
Headquarters535 W 24TH STREET, NEW YORK, NY, 10011
BIOPHARMAWATCH ELITE PLUS
Trade the next NGNE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime